Spis treści:
1. REPORT
2. ESAP METADATE
3. INFORMATION ABOUT THE ENTITY
4. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
1. REPORT
2. ESAP METADATE
3. INFORMATION ABOUT THE ENTITY
4. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
- INSIDE_SFA_July_2026_Sales_20082026_EN.rarUpdated preliminary sales revenue data for July 2026
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 222 | / | 2026 | ||||||||
| Date of issue: | 2026-08-20 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Updated preliminary sales revenue data for July 2026 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 2 Ustawy o ofercie – informacje bieї№ce i okresowe | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, August 20, 2026 – “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) pursuant to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), hereby informs that in July 2026 the Company reported a 103% increase in sales compared to the same month of the previous year, including a 31% increase in domestic sales and a 151% increase in export sales. For the period from the beginning of 2026 through the end of July, the Company reported a 52% increase in sales compared to the same period of the previous year, including a 2% increase in domestic sales and an 82% increase in export sales. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| INSIDE_SFA_July_2026_Sales_20082026_EN.rar INSIDE_SFA_July_2026_Sales_20082026_EN.rar | Updated preliminary sales revenue data for July 2026 | ||||||||||
| Legal framework | Type of information | ||||
| TRANSD | Inside information | ||||
| RegulatoryData | |||||
| Collection Body | PLKNF | ||||
| Unique data record identifier | |||||
| Type of submission | New (to be used for new information) | ||||
| Voluntary information flag |  | ||||
| Date or period covered [Date or beginning of the period to which the information relates] | 2026-07-01 | ||||
| Date or period covered [Date or end of the period to which the information relates] | 2026-07-31 | ||||
| Personal data flag | | ||||
| Macierzyste państwo członkowskie, w stosownych przypadkach | PL | ||||
| DocumentReference | |||||
| Język, w którym przekazano informacje | Oryginał (ORIG) czy tłumaczenie (TRAN) | Numer referencyjny pliku danych | |||
| PL | ORIG | ||||
| SubmittingEntity | |||||
| Submitting entity LEI | or | Submitting entity name - natural person | |||
| RelatedEntity/LegalPerson | |||||
| Entity LEI | Size of the entity | Industry sector(s) | |||
| 097900BGGW0000048796 | Large undertaking | (acc. NACE): C | |||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2026-08-20 | Ognian Ivanov Donev | Executive Director | |||
